Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DECITABINE vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Decitabine is a hypomethylating agent that incorporates into DNA, inhibiting DNA methyltransferase, leading to DNA hypomethylation and reactivation of silenced genes, thereby restoring normal growth control and differentiation in hematopoietic cells.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
FDA-approved: Treatment of patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).,Off-label: Treatment of acute myeloid leukemia (AML), particularly in older adults not fit for intensive chemotherapy.
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
Decitabine 15 mg/m² intravenously over 3 hours every 8 hours for 3 days, repeated every 6 weeks for myelodysplastic syndromes.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal half-life: 0.5-1.5 hours. Short half-life; administered over 1 hour IV to maintain cytotoxic levels.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Decitabine is primarily metabolized via deamination by cytidine deaminase in the liver and other tissues. It is not extensively metabolized by cytochrome P450 enzymes.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Renal: 45% as unchanged drug; biliary/fecal: negligible (<5%). Hepatic metabolism accounts for remainder.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
30-40% bound, primarily to albumin.
Approximately 85-90% bound to serum albumin.
Vd: 20-40 L/kg (extensive tissue distribution, including CNS).
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
IV: 100%; oral: not clinically relevant (<10% due to deamination).
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
No specific dose adjustment recommended for GFR ≥30 m L/min. Insufficient data for GFR <30 m L/min. Monitor renal function and use caution.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
No dose adjustment specified for Child-Pugh Class A or B. For Child-Pugh Class C, use is not recommended due to lack of data. Monitor hepatic function.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Safety and efficacy not established in pediatric patients. Dosing not defined.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment. Monitor for increased toxicity, especially myelosuppression, in elderly patients with impaired organ function.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
Decitabine should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Myelosuppression and worsening neutropenia may occur. Monitor complete blood counts frequently. There is no known safe level of exposure in pregnancy; women of childbearing potential should be advised to avoid pregnancy during treatment.
None.
Myelosuppression: Neutropenia, thrombocytopenia, and anemia may worsen during treatment; monitor blood counts regularly.,Hepatotoxicity: Elevations of liver enzymes and bilirubin have been reported; monitor hepatic function.,Renal toxicity: Serum creatinine elevations may occur; monitor renal function.,Fetal harm: Can cause fetal harm; advise contraception in women of reproductive potential and avoid pregnancy during treatment.,Tumor lysis syndrome: May occur; ensure adequate hydration and monitor uric acid levels.,Infusion reactions: Hypersensitivity reactions including rash, urticaria, and dyspnea have been reported.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to decitabine or any component of the formulation.,Breastfeeding: Not recommended due to potential for serious adverse reactions in nursing infants.,Pregnancy: Should not be used in pregnant women or those planning pregnancy due to risk of fetal harm.
Hypersensitivity to AURLUMYN or any of its components.
No known food interactions. Avoid grapefruit and grapefruit juice as a general precaution due to potential CYP3A4 interaction, though not specifically studied with decitabine. Maintain adequate hydration.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Decitabine is teratogenic in animals and has the potential to cause fetal harm in humans. In first trimester, there is a high risk of major malformations and fetal death. Second and third trimester exposure may cause growth restriction, myelosuppression, and neurodevelopmental effects. Use contraindicated in pregnancy unless benefit outweighs risk.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
No data on presence in human milk. Due to potential for serious adverse reactions in breastfed infants (e.g., myelosuppression, carcinogenesis), breastfeeding is contraindicated during therapy and for at least 2 weeks after last dose. M/P ratio unknown.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No specific dosing adjustment guidelines exist for pregnant patients. Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance, but no data on required dose modifications. Use lowest effective dose if unavoidable, and monitor for toxicity. Consider alternative agents.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Administer decitabine via IV infusion over 1 hour. Premedicate with antiemetics. Monitor CBC, LFTs, and serum creatinine prior to each cycle. Consider growth factor support for neutropenia. Avoid live vaccines during treatment. Dose adjustment required for renal impairment (Cr Cl < 30 m L/min). Not a vesicant; use central line not mandatory. Synergy with histone deacetylase inhibitors is under investigation. Hypersensitivity reactions (e.g., rash, urticaria) may occur.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Take anti-nausea medication as prescribed before infusion.,Report any signs of infection such as fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, flu nasal spray) while on this medication.,Use effective contraception during treatment and for at least 6 months after.,You may experience fatigue; plan rest periods and avoid driving if drowsy.,Stay well hydrated to reduce risk of kidney problems.,Rarely, you may have a severe allergic reaction; seek emergency help for hives, difficulty breathing, or swelling.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
"Decitabine may decrease the cardiotoxic activities of Digitoxin."
"Decitabine may decrease the cardiotoxic activities of Deslanoside."
"The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Decitabine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DECITABINE vs AURLUMYN, answered by our medical review team.
DECITABINE is a Antineoplastic Agent (DNA Demethylating Agent) that works by Decitabine is a hypomethylating agent that incorporates into DNA, inhibiting DNA methyltransferase, leading to DNA hypomethylation and reactivation of silenced genes, thereby restoring normal growth control and differentiation in hematopoietic cells.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DECITABINE and AURLUMYN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DECITABINE is: Decitabine 15 mg/m² intravenously over 3 hours every 8 hours for 3 days, repeated every 6 weeks for myelodysplastic syndromes.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DECITABINE and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DECITABINE is classified as Category C. Decitabine is teratogenic in animals and has the potential to cause fetal harm in humans. In first trimester, there is a high risk of major malformations and fetal death. Second an. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.